Our top pick for
10X Genomics Inc is a health information services business based in the US. 10X Genomics shares (TXG) are listed on the NASDAQ and all prices are listed in US Dollars. 10X Genomics employs 1,239 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$46.20|
|52-week range||$35.15 - $208.99|
|50-day moving average||$48.98|
|200-day moving average||$104.74|
|Wall St. target price||$88.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.80|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-24)||-6.91%|
|1 month (2022-06-01)||0.13%|
|3 months (2022-04-01)||-43.05%|
|6 months (2021-12-31)||-68.98%|
|1 year (2021-07-01)||-75.68%|
|2 years (2020-07-01)||-47.50%|
|3 years (2019-06-27)||N/A|
|5 years (2017-06-27)||N/A|
Valuing 10X Genomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of 10X Genomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
10X Genomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.1 million.
The EBITDA is a measure of a 10X Genomics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$499.2 million|
|Gross profit TTM||$416.4 million|
|Return on assets TTM||-5.4%|
|Return on equity TTM||-11.43%|
|Market capitalisation||$5.3 billion|
TTM: trailing 12 months
We're not expecting 10X Genomics to pay a dividend over the next 12 months.
10X Genomics's shares were split on a 1:2 basis on 16 July 2006. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 10X Genomics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for 10X Genomics shares which in turn could have impacted 10X Genomics's share price.
Over the last 12 months, 10X Genomics's shares have ranged in value from as little as $35.15 up to $208.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 10X Genomics's is 1.9146. This would suggest that 10X Genomics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
10x Genomics, Inc. , a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.